NBY
AMEX · Pharmaceuticals
Novabay Pharmaceuticals Inc
$1.27
+0.27 (+27.00%)
Financial Highlights (FY 2026)
Revenue
117.75M
Net Income
-86,949,597
Gross Margin
66.3%
Profit Margin
-73.9%
Rev Growth
+5.1%
D/E Ratio
0.34
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 66.3% | 66.3% | 57.3% | 57.3% |
| Operating Margin | -59.8% | -53.8% | 32.8% | 31.8% |
| Profit Margin | -73.9% | -70.2% | 22.7% | 21.8% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 117.75M | 112.01M | 19.57M | 22.58M |
| Gross Profit | 78.02M | 74.22M | 11.22M | 12.95M |
| Operating Income | -70,446,943 | -60,314,163 | 6.41M | 7.17M |
| Net Income | -86,949,597 | -74,443,148 | 4.44M | 4.92M |
| Gross Margin | 66.3% | 66.3% | 57.3% | 57.3% |
| Operating Margin | -59.8% | -53.8% | 32.8% | 31.8% |
| Profit Margin | -73.9% | -70.2% | 22.7% | 21.8% |
| Rev Growth | +5.1% | +5.1% | -0.9% | +13.1% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 6.63M | 6.63M | 20.34M | 18.54M |
| Total Equity | 19.33M | 19.33M | 41.21M | 43.15M |
| D/E Ratio | 0.34 | 0.34 | 0.49 | 0.43 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -86,095,187 | -77,806,723 | 7.02M | 9.17M |
| Free Cash Flow | — | — | 4.00M | 3.41M |